[posting]27539173[/posting]Solagran könnte in diesem jahr zu den ganz grossen gewinner gehören .
http://www.aspecthuntley.com.au/docserver/00691853.pdf?filei…
Company Announcement 9 February, 2007
Bioeffectives to be Featured in European Gastroenterology Conference
The Directors of Solagran Limited are pleased to announce that the findings of recent trials
with both Ropren (Bioeffective R) and Bioeffective A will be presented at a major
international Gastroenterology conference to be held in St Petersburg in May 2007. The
conference, which is part of the 9th International Slovenian-Baltic Scientific Forum, will be
attended by around 2,000 Gastroenterology and Hepatology specialists from many countries
throughout Eastern, Central and Western Europe – and particularly from Germany, France,
Russia and the Ukraine.
There is a growing awareness among the medical research community in Europe in relation
to the potential impact of the impending entry of Ropren into the Russian Pharmacopoeia. As
a result, Professor Elena Lapteva, the Professor of Gastroenterology at the St Petersburg
Medical Academy of Postgraduate Studies, and the Head Physician of St Petersburg’s
LENMed Centre, contacted the company this week and requested that Solagran make its
Executive Chairman, Dr Vagif Soultanov, available to present on two topics of great interest
to her professional colleagues:
�� The expected impact of the use of Ropren as a new and highly effective hepatoprotective
substance
�� The potential contribution that Bioeffective A could make to the eradication of
Helicobacter Pylori
Professor Lapteva made it clear in her letter that the development of a new and highly
effective but low side effect hepatoprotective substance, and the emerging possibility of a low
side effect means with which to eradicate Helicobacter Pylori, are two of the most interesting and crucial areas of research for Gastroenterologists and Hepatologists world wide.
She indicated that the experience Dr Soultanov had gained from Solagran’s clinical studies
of Ropren and Bioeffective A would represent a significant contribution to the conference.
The Solagran Board has agreed that Dr Soultanov should participate as the benefits to
Solagran will also be significant. The Directors believe that the opportunity to present to so
many opinion-leading clinicians right at the time that Solagran expects Ropren to be entering
the Russian market could have very positive commercial consequences for the Company.